Drugmakers delay some European launches with a wary eye on Trump's pricing policies - Reuters

Pharmaceutical companies are delaying the European launch of some drugs due to concerns about the Trump administration's drug pricing policies. The companies are adopting a cautious approach as the White House has signaled its intent to take aggressive action on medication costs, a priority that could reshape pricing strategies globally. By holding back European rollouts, drugmakers appear to be reassessing their commercial strategies and avoiding potential exposure to pricing pressure that could follow if products reach the market. The delays suggest the industry views Trump's pricing agenda as a significant enough threat to alter the typical timeline for bringing new medications to European markets. This dynamic underscores how U.S. drug policy decisions can have ripple effects on international pharmaceutical markets and product availability.